April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Retinal structure and function in Achromatopsia: the CNGA3 phenotype
Author Affiliations & Notes
  • Ditta Zobor
    Institute for Ophthalmic Research, Centre for Ophthalmology, Tuebingen, Germany
  • Franco Stanzial
    Genetic Counseling, Coordinating Center of Rare Diseases, Bolzano, Italy
  • Ulrich Kellner
    Rare Retinal Disease Center, Augenzentrum Siegburg, Siegburg, Germany
  • Günther Rudolph
    Department of Ophthalmology, University of Munich, Munich, Germany
  • Bernd Wissinger
    Institute for Ophthalmic Research, Molecular Genetics Laboratory, Tuebingen, Germany
  • Susanne Kohl
    Institute for Ophthalmic Research, Molecular Genetics Laboratory, Tuebingen, Germany
  • Eberhart Zrenner
    Institute for Ophthalmic Research, Centre for Ophthalmology, Tuebingen, Germany
  • Footnotes
    Commercial Relationships Ditta Zobor, None; Franco Stanzial, None; Ulrich Kellner, None; Günther Rudolph, None; Bernd Wissinger, None; Susanne Kohl, None; Eberhart Zrenner, Neurotech USA (C), Pfizer USA (C), QLT Inc. (C), Retina Implant AG Germany (C), Retina Implant AG Germany (F), Retina Implant AG Germany (I), Retina Implant AG Germany (P), Servier Paris (C), Steinbeis GmbH Stuttgart Germany (C), Steinbeis GmbH Stuttgart Germany (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 346. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ditta Zobor, Franco Stanzial, Ulrich Kellner, Günther Rudolph, Bernd Wissinger, Susanne Kohl, Eberhart Zrenner; Retinal structure and function in Achromatopsia: the CNGA3 phenotype. Invest. Ophthalmol. Vis. Sci. 2014;55(13):346.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate retinal function, and to characterize the retinal changes in patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene by using spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF)

Methods: ACHM patients with known mutations in the CNGA3 gene were examined. A complete ophthalmological examination was performed by the same investigator in every patient including psychophysical tests (ETDRS visual acuity, color vision tests, visual field, microperimetry and dark adaptation thresholds) and extended electrophysiology (Ganzfeld and multifocal ERG). The appearance and thickness of all retinal layers were evaluated by SD-OCT and FAF.

Results: Thirty patients (mean age 33.7 years, range: 7 to 56 years) were included. Mean BCVA was 20/140 in the complete forms (cACHM, 28 cases) and 20/60 in the incomplete cases (iACHM, 2 cases). The Rayleigh anomaloscope matches were consistent with a rod-dominated function in every cACHM patient. Microperimetry indicated an overall lower retinal sensitivity within 20° of visual field. In the electrophysiological examinations, photopic responses were non-detectable in cACHM patients, but residual cone responses could be observed in the iACHM patients. ISCEV rod threshold amplitudes and implicit times were within normal limits, while Vmax was significantly below normal values (p<0.05). In contrast, slope (n) and semisaturation intensity (k) were found to be within normal limits. On the morphological level, SD-OCT examination showed no specific changes in 22.2%, IS disruption at the fovea in 36.2%, absent IS in 22.2%, an “intraretinal bubble“ in 13.8% and outer retinal atrophy including RPE loss was seen in 5.6% of all cases. Foveal hypoplasia was found in 21 patients (70%), but surprisingly, no correlation with BCVA could be observed. The severity of morphological and functional changes lacked a robust association with age. A specific correlation to the genotype could not be observed.

Conclusions: Thirty CNGA3-related ACHM patients were examined with identical functional and morphological methods. In preparation to a therapeutic gene therapy trial, high-resolution techniques were used to assess photoreceptor structure and function in patients with ACHM. These findings will be useful for the identification of patients concerning future therapeutic trials. The data imply that the therapeutic window seems to be wider than previously indicated.

Keywords: 507 electrophysiology: clinical • 539 genetics • 696 retinal degenerations: hereditary  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×